Clinician experiences of employing the AmpliChip CYP450 test in routine psychiatric practice

Journal of Psychopharmacology

Volumn 26, Issue 3, 2012, Pages 390-397

  Dunbar, Lucy ^a   Butler, Rachael ^a   Wheeler, Amanda ^a   Pulford, Justin ^a   Miles, Wayne ^a   Sheridan, Janie ^b  

^a WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

antipsychotic agents; attitude; cytochrome p 450 cyp2d6; genotype; pharmacogenetics; qualitative research; risperidone

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; RISPERIDONE;

AMPLICHIP CYP450 TEST; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; DOSE RESPONSE; DRUG METABOLISM; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH PERSONNEL ATTITUDE; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; MENTAL HEALTH SERVICE; NEW ZEALAND; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PSYCHIATRY; PSYCHOSIS; QUALITATIVE RESEARCH; WORK EXPERIENCE;

ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; BIOTRANSFORMATION; COMMUNITY MENTAL HEALTH CENTERS; CYTOCHROME P-450 CYP2D6; GENOTYPING TECHNIQUES; HUMANS; INDIVIDUALIZED MEDICINE; MATERIALS TESTING; MENTAL DISORDERS; MOOD DISORDERS; NEW ZEALAND; PHARMACOGENETICS; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RISPERIDONE;

EID: 84857859339     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106957     Document Type: Article

References (16)

1. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci. 1992 ; 13: 434-439
2. De Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006a ; 47: 75-85 (Pubitemid 43017126)
3. De Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther. 2006b ; 10: 135-151 (Pubitemid 43974591)
4. De Leon J, Susce MT, Pan RM. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiat. 2005 ; 66: 15-27
5. Dunbar L, Miles W, Wheeler A, Sheridan J, Pulford J, Butler R. The CYP2D6 metaboliser status of patients prescribed risperidone for the treatment of psychosis. New Zeal Med J. 2009 ; 122: 29-34
6. Gurwitz D, Weizman A, Rehavi M. Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci. 2003 ; 24: 122-125 (Pubitemid 36293777)
7. Hayward R. Clinical decision support tools: do they support clinicians?. Future Practice. 2004 ; 2004: 66-68
8. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999 ; 20: 342-349 (Pubitemid 29366813)
9. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998 ; 18: 84-112 (Pubitemid 28059007)
10. Mrazek A. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. CNS Spectr. 2006 ; 11: 1-4
11. Musana AK, Wilke RA. Gene-based prescribing: clinical implications of the cytochrome P450 genes. Wisc Med J. 2005 ; 104: 61-66 (Pubitemid 43150912)
12. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?. Am J Hum Genet. 1997 ; 60: 265-271 (Pubitemid 27058398)
13. Mental health service use in New Zealand, 2004. Wellington: Ministry of Health ; 2007 :
14. Roberts RL, Begg EJ, Joyce PR, Kennedy MA. How the pharmacogenetics of cytochrome P450 enzymes may affect prescribing. New Zeal Med J. 2002 ; 115: 137-140 (Pubitemid 36004437)
15. Van der Weide J, Hinrichs JW. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem. Reviews. 2006 ; 27: 17-25
16. Wheeler A. A typical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions. New Zeal Med J. 2006 ; 119: U2055